XVARY Composite Score
41
/ 100
Below Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Jasper is a biotech company betting briquilimab can treat itchy skin disease, blood disorders, and transplant prep.
How it gets paid
Last year Jasper Therapeutics made n/a in revenue. Chronic spontaneous urticaria was the main engine at $0.0M, or 35% of sales.
What just happened
Jasper posted $0.0M in revenue and lost $1.62 a share in the quarter shown in the underlying feed.
At a Glance
C++ balance sheet — some cracks in the foundation
-$4.89 fy2024 eps est
Operating margin not meaningful — pre-revenue burn
1.9 beta
~$34M market cap
XVARY composite: 41/100 — below average
What They Do
Jasper is a biotech company betting briquilimab can treat itchy skin disease, blood disorders, and transplant prep.
Sixty-four employees are carrying one antibody and 3 disease shots. That is tiny, but 145+ dosed participants are real bodies, not slide-deck biology. You also get an exclusive Amgen license, which is permission to use and sell the drug worldwide.
How They Make Money
n/a
annual revenue
Chronic spontaneous urticaria
$0.0M
MDS
$0.0M
Stem cell conditioning
$0.0M
SCD
$0.0M
FA and SCID
$0.0M
The Products That Matter
Lead antibody program
briquilimab
$0 commercial revenue
This is the program carrying the equity story, and the business still shows $0 commercial revenue. If the science works, the narrative changes. If it does not, the rest of the model has very little to stand on.
core thesis
Broader clinical optionality
clinical pipeline
~$34M equity value
At a market cap of roughly $34M, the market is not paying much for pipeline optionality today. That can be an opportunity if data improve, or a warning if you were assuming hidden asset value.
optionality
Financing capacity
balance sheet
C++ balance sheet grade
A C++ balance sheet is not a side detail for a company losing on the order of ~$4.89 per share in the FY data on this page. In early biotech, funding is part of the product because it determines whether the clinical story survives long enough to be tested.
survival
Key Numbers
$34M
market cap
At $34M, one bad trial or one financing can move the whole company like a rounding error.
1.9
beta
A beta of 1.9 means the stock moves about 1.9 times the market's mood swings.
145+
dosed participants
145+ dosed people is the first real proof that the drug has left the lab.
64
employees
64 employees is a tiny headcount for a company trying to sell a one-drug story worldwide.
Financial Health
C++
Strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
C++ — below average. watch for debt servicing and cash burn.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
missed estimates
Jasper posted $0.0M in revenue and lost $1.62 a share in the quarter shown in the underlying feed.
Full-year EPS was -$4.89, after quarterly losses of -$1.03, -$0.97, -$1.24, and -$1.62. No revenue is reported in the supplied data, so the business is still all burn.
$0.0M
revenue
-$1.62
q4 eps
-$4.89
fy eps
Q4 loss
The $1.62 quarterly loss matters because it was worse than Q3's $1.24, and revenue is still $0.0M in the data.
source: quarterly EPS history; Yahoo Finance revenue and trailing EPS
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk here is briquilimab failing to produce convincing clinical evidence. When one asset carries most of the story and the company is worth about $34M, there is not much room for disappointment to hide.
Med
Clinical readout misses
Jasper is still effectively a one-program company. If briquilimab data disappoint, the market does not have a second commercial engine to fall back on.
This would hit the core thesis directly because the business currently shows effectively $0 commercial revenue outside the pipeline story.
Med
Cash gets raised from a position of weakness
A C++ balance sheet and ongoing losses mean financing risk is never far away. If timelines slip or sentiment stays weak, new capital can arrive at prices existing holders will not enjoy.
At a ~$34M market cap and $1.14 share price, dilution does not need to be massive to matter.
Med
Single-asset concentration never turns into a platform
Management can talk about broader optionality, but the market is still paying mainly for briquilimab. If that does not broaden, the multiple stays pinned to one uncertain outcome.
That leaves the stock trading as a binary event vehicle rather than a biotech building durable asset value.
Med
Thin coverage and weak price stability amplify every headline
Price stability is 5 / 100 and beta is 1.9. On a stock this small, sentiment swings can become valuation swings before fundamentals have time to catch up.
You can be directionally right on the science and still get punished by timing, financing, or liquidity.
This combined risk picture sits on top of a $34M equity value, a $1.14 stock price, and effectively $0 commercial revenue. That is why trial evidence and financing terms matter more here than traditional valuation ratios.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Timeline
The next company update on briquilimab
This is the first thing to read, not the tenth. On a one-asset story, a cleaner timeline is progress. A vaguer timeline is a warning.
Metric
Cash needs versus share price
With a ~$34M market cap and a $1.14 stock price, funding math matters. If capital is needed before a meaningful catalyst, existing holders pay for the wait.
Risk
Whether briquilimab remains the only reason to own it
If every update still circles back to the same single program, the diversification story is still just a promise.
Trend
The gap between the $10.50 target and the $1.14 tape
That spread closes one of two ways: evidence improves and the stock rises, or the target comes down to meet reality. Both outcomes are information.
Analyst Rankings
short-term outlook
mixed
coverage is thin and conviction is thin with it. in human-speak, analysts are leaving a lot of the story to the next catalyst.
risk profile
volatile
A 1.9 beta and 5 / 100 price stability tell you this will not behave like a steady compounder.
chart momentum
catalyst-driven
This tape trades more on financing and trial expectations than on smooth operating trends, because there are almost no operating trends yet.
earnings predictability
40 / 100
Losses are expected, but the pace still depends on development spend and financing choices. That makes the reported numbers inherently noisy.
Source: institutional data
Institutional Activity
institutional ownership data for JSPR is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$1
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive